JPH07110332A - Inspection reagent and detection method for tubercle bacillus - Google Patents

Inspection reagent and detection method for tubercle bacillus

Info

Publication number
JPH07110332A
JPH07110332A JP25399193A JP25399193A JPH07110332A JP H07110332 A JPH07110332 A JP H07110332A JP 25399193 A JP25399193 A JP 25399193A JP 25399193 A JP25399193 A JP 25399193A JP H07110332 A JPH07110332 A JP H07110332A
Authority
JP
Japan
Prior art keywords
mpb64
liquid
culture
tubercle bacillus
mycobacterium tuberculosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP25399193A
Other languages
Japanese (ja)
Inventor
Tetsuo Tomiyama
哲雄 富山
Takashi Yamaguchi
隆司 山口
Kazuhiro Matsuo
和浩 松尾
Akihiro Yamazaki
晤弘 山崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP25399193A priority Critical patent/JPH07110332A/en
Publication of JPH07110332A publication Critical patent/JPH07110332A/en
Pending legal-status Critical Current

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

PURPOSE:To make it possible to detect tubercle bacillus quickly by incubating a specimen in a liquid culture medium to detect MPB64 secreted into a culture liquid immunologically. CONSTITUTION:Colibacillus stock containing fused protein manifestation vector pMAL64c is incubated, the culture bacillus body is crushed by an ultrasonic wave and the top of the crushed liquid is taken centrifugally to prepare MPB64 purely from the supernatant fraction. Antiserum can be obtained easily by immunizing an animal able to produce antibodies, for example, guinea pigs, rabbits and sheep with the MPB64. To detect tubercle bacillus using this anti- MPB64 antiserum, the tubercle bacillus in a specimen is incubated in a liquid culture medium. For example, after one week, the MPB64 secreted into the culture liquid is detected immunologically. As for the detection method for the purpose, reversed passive blood cell agglutination reaction and reversed passive latex agglutination reaction are ideal.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、MPT64を免疫学的
に検出することによって結核菌を特異的に検出する試薬
に関する。更に詳しくは、液体培地で検体中の結核菌を
培養し、この培養液中に産生されたMPT64を免疫学
的に同一のMPB64に対する抗MPB64抗体によっ
て免疫学的に検出する結核菌検査試薬及び検出方法に関
する。
TECHNICAL FIELD The present invention relates to a reagent for specifically detecting Mycobacterium tuberculosis by immunologically detecting MPT64. More specifically, a tubercle bacillus test reagent and a method for culturing M. tuberculosis in a sample in a liquid medium and immunologically detecting MPT64 produced in the culture medium by an anti-MPB64 antibody against MPB64 which is immunologically identical Regarding the method.

【0002】[0002]

【従来の技術】ヒトの結核は、結核菌(Mycobacterium t
uberculosis)の感染によって惹起される呼吸器などの感
染症であることは周知の通りである。結核の大多数を占
める肺結核は、肺癌、肺真菌症、肺吸虫症などと臨床的
に鑑別するのは困難なことが多く、確定診断はもっぱら
検体の培養により結核菌を検出する方法にたよってい
る。しかし、結核菌の培養は、通常小川培地を用いて4
〜8週間を必要とし、更に検出菌の同定が必須である。
2. Description of the Related Art Mycobacterium tuberculosis is mycobacterium tuberculosis.
It is well known that this is an infectious disease of the respiratory tract caused by the infection of uberculosis). Pulmonary tuberculosis, which makes up the majority of tuberculosis, is often difficult to distinguish clinically from lung cancer, pulmonary mycosis, paragonimiasis, etc., and the definitive diagnosis is solely based on the method of detecting Mycobacterium tuberculosis by culturing specimens. There is. However, the culture of Mycobacterium tuberculosis is usually performed using Ogawa's medium.
~ 8 weeks are required, and the identification of the detected bacteria is essential.

【0003】[0003]

【発明が解決しようとする課題】上記のように、従来の
方法で結核菌を検出するには長期間を必要とするため、
結核の確定診断および早期の治療に大きな障害となって
いるばかりではなく、排菌による周囲の人への感染など
公衆衛生上も問題が大きい。また、結核菌を免疫学的に
検出する方法は従来全く知られていない。本発明は、結
核菌を免疫学的に特異的にかつ迅速に検出することがで
きる検査試薬及び検出方法を提供するものである。
As described above, it takes a long time to detect Mycobacterium tuberculosis by the conventional method.
Not only is it a major obstacle to the definite diagnosis and early treatment of tuberculosis, but it also poses a serious public health problem, such as infection of people around by the bacillus. Further, no method for immunologically detecting Mycobacterium tuberculosis has been known so far. The present invention provides a test reagent and a detection method that can detect Mycobacterium tuberculosis immunologically specifically and rapidly.

【0004】[0004]

【課題を解決するための手段】前記の問題を解決するた
め、本発明者等は、結核菌のみが産生する蛋白、MPB
64に着目し、喀痰などの検体を液体培地で培養し、培
養液中に分泌されたMPB64を免疫学的に検出するこ
とによって、迅速、確実に結核菌を検出する試薬の開発
に成功し、本発明を完成するに至った。更に、この特異
的検出法は、培養された未知分離菌の同定、迅速な薬剤
感受性試験にも応用することができる。
In order to solve the above problems, the present inventors have found that MPB, a protein produced only by Mycobacterium tuberculosis,
Focusing on 64, by culturing a specimen such as sputum in a liquid medium and immunologically detecting MPB64 secreted in the culture medium, a reagent for detecting Mycobacterium tuberculosis rapidly and reliably was successfully developed, The present invention has been completed. Furthermore, this specific detection method can be applied to the identification of cultured unknown isolates and rapid drug susceptibility testing.

【0005】本発明は、抗MPB64抗体からなる、結
核菌を免疫学的に検出するための結核菌検査試薬及びそ
れを用いて免疫検定法により結核菌を検出する方法であ
る。MPB64は、1986年M. Harboe 等によりBCG菌
が産生する蛋白の中から分離精製され、そのN末端付近
のアミノ酸配列が報告されている(Infection and Immun
ity vol.52, 293-302, 1986)。結核菌は数百種類の蛋白
を培養液中に分泌するが、MPT64は結核菌におい
て、MPB64はBCG菌においてのみ産生される種特
異蛋白であり、両者は、免疫学的に同一である。
The present invention is a tubercle bacillus test reagent for immunologically detecting tubercle bacillus comprising an anti-MPB64 antibody, and a method for detecting tubercle bacillus by an immunoassay using the reagent. MPB64 was isolated and purified from the protein produced by BCG bacteria by M. Harboe et al. In 1986, and the amino acid sequence near its N-terminus has been reported (Infection and Immun
ity vol.52, 293-302, 1986). Mycobacterium tuberculosis secretes several hundred kinds of proteins into the culture medium, but MPT64 is a species-specific protein produced only in Mycobacterium tuberculosis and MPB64 is produced in BCG bacterium, and both are immunologically identical.

【0006】このMPB64を結核菌培養液中の数百種
類の蛋白から純粋に分離するためには多大の労力と時間
を要し、しかもその収量は非常に少なく、検査試薬の原
料に供するのは極めて困難であったが、本発明者等は、
特開平1−247094号においてMPB64遺伝子を
クローニングし、全塩基配列を決定し、大腸菌でMPB
64を純粋に直接発現することに成功した。更に改良を
加えて、より大量に発現できる技術を開発した。すなわ
ち、融合蛋白発現ベクターpMAL64cを含む大腸菌
株(FERMP−13762)を培養し、この培養菌体
を超音波で破砕し、遠心によって破砕液上清を分取し、
この上清画分よりMPB64を純粋に調製することがで
きる。また、スメグマ菌のような結核菌の類縁菌を宿主
として用い、上記MPB64遺伝子を導入して、菌体外
に直接分泌発現させ、培養上清から大量のMPB64を
純粋に調製することも可能である。
It takes a great deal of labor and time to purely separate MPB64 from several hundred kinds of proteins in the culture solution of Mycobacterium tuberculosis, and the yield thereof is very small. Although it was extremely difficult, the present inventors
MPB64 gene was cloned in Japanese Patent Laid-Open No. 1-247094, the entire base sequence was determined, and MPB was isolated in E. coli.
We have succeeded in expressing 64 directly. With further improvement, we have developed a technology that enables greater expression. That is, an Escherichia coli strain (FERMP-13762) containing the fusion protein expression vector pMAL64c was cultured, the cultured bacterial cells were disrupted by ultrasonic waves, and the disrupted liquid supernatant was collected by centrifugation.
MPB64 can be prepared purely from this supernatant fraction. It is also possible to prepare a large amount of MPB64 purely from the culture supernatant by using the above-mentioned MPB64 gene as a host and using a related strain of Mycobacterium tuberculosis such as Smegma as a host to directly secrete and express it. is there.

【0007】このMPB64を免疫学的に検出するため
の抗血清は、MPB64を抗体産生能のある動物、例え
ばモルモット、ウサギ、ヒツジ、ヤギに通常の方法で免
疫することによって容易に得られる。この抗MPB64
抗血清を用いて、結核菌を検出するには、検体中の結核
菌を液体培地で培養し、例えば1週間後に、培養液中に
分泌されたMPB64を免疫学的に検出すればよい。免
疫学的検出法として、逆受身血球凝集反応(RPH
A)、逆受身ラテックス凝集反応(RPLA)、酵素免
疫抗体法(EIA)等をはじめとして、多くの免疫学的
検定法が適用できる。これらの方法により高感度でMP
B64を検出することができるが、結核菌のバイオハザ
ード対策として、安全キャビネットの中で検査できるこ
とが望ましいので、RPHAおよびRPLAが特に望ま
しい。RPHA法を行うためには、タンニン酸処理固定
ヒトO型赤血球またはヒツジ赤血球に抗MPB64抗体
を感作し、これを試験管またはマイクロプレート中で検
体の結核菌培養液またはその希釈液に加えてから静置
し、1〜3時間後に管底凝集像として判定できる。赤血
球の代りにポリスチレンなどのラテックスを担体とした
RPLAも同様に有用な方法である。いづれの方法にお
いても、管底凝集がおこればMPB64の存在が確認で
き、結核菌が培養されたことが証明される。また、この
反応は、極めて容易に、しかも安全キャビネットの中で
も実施できるので、臨床検査に特に適している。
The antisera for immunologically detecting MPB64 can be easily obtained by immunizing animals having antibody-producing ability, such as guinea pig, rabbit, sheep and goat, with MPB64 by a conventional method. This anti-MPB64
In order to detect Mycobacterium tuberculosis using an antiserum, the Mycobacterium tuberculosis in a sample may be cultured in a liquid medium and, for example, one week later, MPB64 secreted in the culture medium may be immunologically detected. Reverse passive hemagglutination (RPH)
Many immunological assay methods can be applied including A), reverse passive latex agglutination reaction (RPLA), enzyme immunoassay method (EIA) and the like. MP with high sensitivity by these methods
B64 can be detected, but RPHA and RPLA are particularly preferable because it is desirable that they can be tested in a safety cabinet as a biohazard countermeasure against Mycobacterium tuberculosis. In order to perform the RPHA method, anti-MPB64 antibody was sensitized to tannic acid-treated fixed human O-type red blood cells or sheep red blood cells, and this was added to a tubercle bacillus culture solution or its diluted solution in a test tube or a microplate. It can be determined as a tube bottom aggregation image after 1 to 3 hours. RPLA using a latex such as polystyrene as a carrier instead of red blood cells is also a useful method. In any method, if tube bottom aggregation occurs, the presence of MPB64 can be confirmed, demonstrating that the tuberculosis bacterium has been cultured. This reaction is also particularly suitable for clinical examinations because it can be performed very easily and in a safety cabinet.

【0008】[0008]

【発明の効果】以上のように、従来結核菌の培養に、4
〜8週間を要していたのが、抗MPB64抗体を用いて
免疫学的に検出すれば1週間の培養で足り、しかも同時
に、結核菌であることの確認が確実にできるので、結核
患者の早期確定診断および早期治療が可能となる。
INDUSTRIAL APPLICABILITY As described above, it is possible to use the conventional 4
It took ~ 8 weeks, but if immunologically detected using anti-MPB64 antibody, one week of culture is sufficient, and at the same time, it can be surely confirmed that it is Mycobacterium tuberculosis. It enables early definite diagnosis and early treatment.

【0009】[0009]

【実施例】 実施例1. MPB64の生産 融合蛋白発現ベクターpMAL64cを含むE. coli JM
109 株(FERMP−13762)を、一晩培養した培
養液40mlをL−ブロス培地4リットル(アンピシリン
100mg/l含有)に加えた。37℃で4時間培養した
後、イソプロピル−1−チオ−β−D−ガラクトシド
(IPTG)を最終濃度0.3mMになるように加え、さ
らに3時間培養した。この培養液を氷冷し、遠心(8,
000rpm で10分間)して集菌した後、200mlのカ
ラムバッファー(10mM Tris-Cl(pH7.4)、200mM NaCl、1mM
EDTA、1mMアジ化ナトリウム、1mM ジチオトレイトール)
に懸濁し、−20℃で一晩凍結した。融解後、超音波細
胞破砕装置(東湘電気製UCD−200T型)により菌
体を破砕した。再度遠心して破砕液の上清を集めた。上
清をアミロース樹脂カラム(マルトースバインディング
プロテインを吸着できる、米国、NEB社製)20mlに
通し、8倍量のカラムバッファーで洗浄した。次に、1
0mMマルトースを含むカラムバッファーにより吸着した
融合蛋白を溶出させ、280nmの吸光度を指標に蛋白含
有画分(150mg相当量)を集めた。
EXAMPLES Example 1. Production of MPB64 E. coli JM containing fusion protein expression vector pMAL64c
The 109 strain (FERMP-13762) was added to 4 liters of L-broth medium (containing 100 mg / l ampicillin) of 40 ml of a culture solution obtained by overnight culture. After culturing at 37 ° C. for 4 hours, isopropyl-1-thio-β-D-galactoside (IPTG) was added to a final concentration of 0.3 mM, and the cells were further cultured for 3 hours. This culture solution is ice-cooled and centrifuged (8,
After collecting the cells at 000 rpm for 10 minutes, 200 ml of column buffer (10 mM Tris-Cl (pH7.4), 200 mM NaCl, 1 mM)
EDTA, 1 mM sodium azide, 1 mM dithiothreitol)
And suspended at −20 ° C. overnight. After thawing, the cells were disrupted by an ultrasonic cell disruption device (Tosho Denki UCD-200T type). The mixture was centrifuged again and the supernatant of the disrupted solution was collected. The supernatant was passed through 20 ml of an amylose resin column (manufactured by NEB, USA, capable of adsorbing maltose binding protein) and washed with 8 times the column buffer. Then 1
The adsorbed fusion protein was eluted with a column buffer containing 0 mM maltose, and the protein-containing fraction (150 mg equivalent amount) was collected using the absorbance at 280 nm as an index.

【0010】実施例2. MPB64の精製 実施例1で得た蛋白含有画分にプロテアーゼFactor Xa
(米国、NEB社製)250μg を加え、25℃で72
時間おいた。切断溶液をそのままヒドロキシアパタイト
カラム(米国、バイオラッド社製)1gにかけた。80
mlのカラムバッファーを流すことによりマルトースを除
去し、次に0.5M リン酸ナトリウム溶液(pH7.0)
を流して蛋白を溶出させた。蛋白含有画分をそのままア
ミロースカラムにかけて切断されたマルトースバインデ
ィング蛋白を吸着させ、目的のリコンビナントMPB6
4蛋白を素通りさせた。MPB64蛋白を含む画分を集
め、濃縮後、20mM Tris-Cl(pH8.0) 含有25mMNaC
l溶液に対して透析した。これをFPLC(スウェーデ
ン、ファルマシア社製)(条件:Mono Qイオン交換カ
ラムを用い、移動相として20mM Tris-Clバッファー(p
H8.0) 中、NaClからなる濃度勾配液を用いる)で精
製し、3.0mgの精製標品を得た。
Embodiment 2. Purification of MPB64 Protease Factor Xa was added to the protein-containing fraction obtained in Example 1.
Add 250 μg (manufactured by NEB, USA), and add 72 at 25 ° C
I had time. The cleavage solution was directly applied to 1 g of a hydroxyapatite column (manufactured by Bio-Rad, USA). 80
Maltose was removed by flowing ml of column buffer, and then 0.5M sodium phosphate solution (pH 7.0).
To elute the protein. The protein-containing fraction is directly applied to an amylose column to adsorb the cleaved maltose binding protein, and the target recombinant MPB6
4 proteins were passed through. Fractions containing MPB64 protein were collected, concentrated, and concentrated to 25 mM NaC containing 20 mM Tris-Cl (pH 8.0).
The solution was dialyzed against 1 solution. This is FPLC (Pharmacia, Sweden) (Conditions: Mono Q ion exchange column is used, and 20 mM Tris-Cl buffer (p
H8.0) in a concentration gradient solution consisting of NaCl) to obtain 3.0 mg of a purified standard product.

【0011】実施例3. 抗MPB64ヤギ血清の作製 実施例2で調製したMPB64を生理食塩水で1mg/ml
溶液とし、この溶液2mlにフロイント完全アジュバント
2mlを混合してからエマルジョンとし、ヤギの背面皮下
および大腿部筋肉内にそれぞれ注射して免疫した。4週
間後、6週間後および8週間後にMPB64、1mg/ml
水溶液を0.5mlづつ静脈注射し、最後の追加免疫の7
日後に全採血し、血清を分離して抗MPB64ヤギ血清
800mlを得た。
Embodiment 3. Preparation of anti-MPB64 goat serum MPB64 prepared in Example 2 was added to physiological saline at 1 mg / ml.
A solution was prepared by mixing 2 ml of this solution with 2 ml of Freund's complete adjuvant and then forming an emulsion, which was then injected subcutaneously into the dorsal skin of the goat and into the muscle of the thigh to immunize. MPB64, 1 mg / ml after 4 weeks, 6 weeks and 8 weeks
The final booster immunization was 7
After a day, whole blood was collected and the serum was separated to obtain 800 ml of anti-MPB64 goat serum.

【0012】実施例4. 精製抗MPB64抗体の調製 実施例3で調製した抗MPB64ヤギ血清(以下抗血清
と称する)2容に飽和硫酸アンモニウム水溶液1容を加
え、室温で1時間処理した後、3,000rpmで30分
遠心して硫酸アンモニウム沈殿画分をとり、生理食塩水
に対して透析して抗体の1/3飽和画分を得た。次にB
rCN−セファロース4B(スエーデン、ファルマシア
社製)充填カラムにMPB64を通して吸着させ、洗浄
後、上記抗体の1/3飽和画分を通して吸着させた後、
酢酸バッファー(pH2.5) を流して抗体を解離させて分取
し、pHを7.2に補正して精製抗MPB64抗体を得
た。
Embodiment 4. Preparation of Purified Anti-MPB64 Antibody 1 volume of saturated ammonium sulfate aqueous solution was added to 2 volumes of anti-MPB64 goat serum (hereinafter referred to as antiserum) prepared in Example 3, treated at room temperature for 1 hour, and then centrifuged at 3,000 rpm for 30 minutes. The ammonium sulfate precipitation fraction was collected and dialyzed against physiological saline to obtain a 1/3 saturated fraction of the antibody. Then B
MPB64 was adsorbed on a column packed with rCN-Sepharose 4B (manufactured by Pharmacia, Sweden), washed, and then adsorbed through a 1/3 saturated fraction of the above antibody.
Acetic acid buffer (pH 2.5) was flown to dissociate the antibody, which was then collected and corrected to pH 7.2 to obtain a purified anti-MPB64 antibody.

【0013】実施例5. 抗体感作血球の作製 グルタールアルデヒド固定ヒツジ赤血球の0.5%PB
S懸濁液1容に、1:100,000タンニン(米国、
NBC社製)を1容加え、室温で15分間処理した後、
PBSで3回洗浄し、1容のPBSに懸濁して0.5%
タンニン血球を得た。このタンニン血球1容に実施例4
で得た精製抗MPB64抗体(4μg/ml)1容を加え、
37℃で30分間処理し、PBSで3回洗浄後、希釈液
(0.1%ウシ血清アルブミン+PBS)1容に懸濁し
て抗体感作血球を得た。この抗体感作血球を用いて、逆
受身血球凝集反応を行ったところ、MPB64の4ng/m
l 以上で管底凝集を示した。
Embodiment 5. Preparation of antibody-sensitized blood cells 0.5% PB of glutaraldehyde-fixed sheep red blood cells
In one volume of S suspension, 1: 100,000 tannin (US,
(Manufactured by NBC Co., Ltd.) and treated at room temperature for 15 minutes,
Wash 3 times with PBS and suspend in 1 volume of PBS to 0.5%
A tannin blood cell was obtained. Example 4 was added to 1 volume of this tannin blood cell.
1 volume of the purified anti-MPB64 antibody (4 μg / ml) obtained in
The cells were treated at 37 ° C. for 30 minutes, washed 3 times with PBS, and then suspended in 1 volume of a diluent (0.1% bovine serum albumin + PBS) to obtain antibody-sensitized blood cells. Using this antibody-sensitized blood cell, a reverse passive hemagglutination reaction was performed.
The above showed tube bottom aggregation.

【0014】結核菌検出例 結核菌検査検体として喀痰を用い、常法によりデュボス
液体培地を用いて培養し、1週間後にMPB64の有無
を次のようにして検査した。マイクロプレートに希釈液
25μl を滴下しておき、この中に液体培養液5μl を
加え、その上に、実施例5で調製した抗体感作血球25
μl を滴下し、3時間後に管底凝集の有無を肉眼で判定
した。対照として、小川培地を用いて常法により8週間
培養した。この結果を表に示す。
Example of detection of Mycobacterium tuberculosis Sputum was used as a test sample for Mycobacterium tuberculosis, and cultured in a Dubos liquid medium by a conventional method, and after 1 week, the presence or absence of MPB64 was examined as follows. 25 μl of the diluting solution was added dropwise to the microplate, 5 μl of the liquid culture solution was added thereto, and the antibody-sensitized blood cells 25 prepared in Example 5 were further added thereto.
μl was dropped, and after 3 hours, the presence or absence of tube bottom aggregation was visually determined. As a control, it was cultured for 8 weeks by a conventional method using Ogawa medium. The results are shown in the table.

【0015】[0015]

【表1】 [Table 1]

【0016】表にみられるように、1週間培養した液中
のMPB64の検出結果と、小川培地で8週間培養によ
る結核菌の検出結果はよく一致し、本発明のMPB64
検出法が小川培地培養法に完全におきかえられることを
示した。このように、MPB64検出法は、結核菌検出
法として迅速、確実な結果を得ることができ、臨床検査
法として適切な方法であることを示した。
As can be seen from the table, the detection result of MPB64 in the liquid cultured for 1 week and the detection result of Mycobacterium tuberculosis by the culture for 8 weeks in Ogawa medium are in good agreement.
It was shown that the detection method could completely replace the Ogawa culture method. As described above, the MPB64 detection method was able to obtain rapid and reliable results as a detection method for Mycobacterium tuberculosis, and was shown to be an appropriate method as a clinical test method.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 松尾 和浩 神奈川県川崎市川崎区鈴木町1−1 味の 素株式会社中央研究所内 (72)発明者 山崎 晤弘 神奈川県川崎市川崎区鈴木町1−1 味の 素株式会社中央研究所内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Kazuhiro Matsuo Kazuhiro Matsuo 1-1, Suzuki-cho, Kawasaki-ku, Kanagawa Prefecture Ajinomoto Co., Inc. Central Research Laboratory (72) Akihiro Yamazaki 1-Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa -1 Central Research Institute of Ajinomoto Co., Inc.

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 抗MPB64抗体からなる、結核菌を免
疫学的に検出するための結核菌検査試薬。
1. A Mycobacterium tuberculosis test reagent for immunologically detecting Mycobacterium tuberculosis, which comprises an anti-MPB64 antibody.
【請求項2】 抗MPB64抗体を用いて免疫学的検定
法により結核菌を検出する方法。
2. A method for detecting Mycobacterium tuberculosis by an immunoassay using an anti-MPB64 antibody.
JP25399193A 1993-10-12 1993-10-12 Inspection reagent and detection method for tubercle bacillus Pending JPH07110332A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP25399193A JPH07110332A (en) 1993-10-12 1993-10-12 Inspection reagent and detection method for tubercle bacillus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP25399193A JPH07110332A (en) 1993-10-12 1993-10-12 Inspection reagent and detection method for tubercle bacillus

Publications (1)

Publication Number Publication Date
JPH07110332A true JPH07110332A (en) 1995-04-25

Family

ID=17258752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP25399193A Pending JPH07110332A (en) 1993-10-12 1993-10-12 Inspection reagent and detection method for tubercle bacillus

Country Status (1)

Country Link
JP (1) JPH07110332A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084481A1 (en) 2007-12-28 2009-07-09 Bl Co., Ltd. Immunodetection assay for mycobacterium tuberculosis complex
JP2010112844A (en) * 2008-11-06 2010-05-20 Kankyo Shizuoka:Kk Method and kit for testing drug sensibility of tubercle bacillus strain
WO2013151122A1 (en) * 2012-04-05 2013-10-10 株式会社ビーエル Method and kit for immunological detection of mycobacterium tuberculosis complex

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084481A1 (en) 2007-12-28 2009-07-09 Bl Co., Ltd. Immunodetection assay for mycobacterium tuberculosis complex
US8541179B2 (en) 2007-12-28 2013-09-24 Bl Co., Ltd. Immunodetection assay for Mycobacterium tuberculosis complex
JP2010112844A (en) * 2008-11-06 2010-05-20 Kankyo Shizuoka:Kk Method and kit for testing drug sensibility of tubercle bacillus strain
WO2013151122A1 (en) * 2012-04-05 2013-10-10 株式会社ビーエル Method and kit for immunological detection of mycobacterium tuberculosis complex
JP5612778B2 (en) * 2012-04-05 2014-10-22 株式会社ビーエル Immunological detection method and detection kit for Mycobacterium tuberculosis group
CN104246505A (en) * 2012-04-05 2014-12-24 株式会社比尔生命 Method and kit for immunological detection of mycobacterium tuberculosis complex
JPWO2013151122A1 (en) * 2012-04-05 2015-12-17 株式会社ビーエル Immunological detection method and detection kit for Mycobacterium tuberculosis group
CN105403700A (en) * 2012-04-05 2016-03-16 株式会社比尔生命 Method And Kit For Immunological Detection Of Mycobacterium Tuberculosis Complex
EP3499237A1 (en) * 2012-04-05 2019-06-19 Tauns Co., Ltd. Method for immunological detection of mycobacterium tuberculosis complex
US10823730B2 (en) 2012-04-05 2020-11-03 Tauns Co., Ltd. Method and kit for immunological detection of Mycobacterium tuberculosis
US10830769B2 (en) 2012-04-05 2020-11-10 Tauns Co., Ltd Method and kit for immunological detection of Mycobacterium tuberculosis
US10883988B2 (en) 2012-04-05 2021-01-05 Tauns Co., Ltd. Method and kit for immunological detection of Mycobacterium tuberculosis complex

Similar Documents

Publication Publication Date Title
JPH05264553A (en) Antigen prepared for detecting helicobacter pyroly
CN101923091B (en) Kit for detecting high-sensitivity mycobacterium tuberculosis
JPWO2009084481A1 (en) Immunodetection method for Mycobacterium tuberculosis group
JP4234207B2 (en) Diagnosis method of allergic bronchopulmonary aspergillosis
US4141965A (en) Assay of immune complexes
WO2008119358A2 (en) Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
JP2005506512A (en) Latent human tuberculosis model, diagnostic antigen, and method of use
JP2001505525A (en) Method for purifying Clostridium difficile toxin A and monospecific antibody
ZA200400843B (en) Early detection of mycobacterial disease using peptides
JPH07110332A (en) Inspection reagent and detection method for tubercle bacillus
US5006463A (en) Immunoassays for discriminating between brucellosis infections and vaccinations
CA1256371A (en) Rapid separation of dirofilaria immitis immune complexes
CN105753982B (en) The immune chromatography reagent kit of anti-human streptococcus pneumonia fam1 family PspA protein antibodies and the application antibody
US20090011442A1 (en) TB diagnostics based on mycobacterium tuberculosis excretory secretory antigens and their specific immunoglobulins
JP3638731B2 (en) Method for extracting multidrug resistant staphylococcal antigens
RU2341288C1 (en) MEDICINE FORMING CELLULAR IMMUNITY FOR MYCOBACTERIUM TUBERCULOSIS H37 Rv, METHOD OF PRODUCTION THEREOF (VERSIONS), RECOMBINANT STRAIN AND TUBERCULOSIS DIAGNOSTIC AGENT
CN105585634B (en) The immune chromatography reagent kit of anti-human streptococcus pneumonia fam2 family PspA protein antibodies and the application antibody
JPH0664065B2 (en) Immunological assay for outer membrane-bearing bacteria
CN105273079B (en) The screening and application of human serum albumin dominant antigen epitope
US4937201A (en) Latex reagent for detection of the toxin of clostridium difficile
CN110862969B (en) Hybridoma cell strain secreting anti-CFP-10 antibody, antibody and application thereof
US20060127960A1 (en) Process for preparation of an agglutination reagent for rapid detection of typhoid
WO1998024885A1 (en) Helicobacter pylori antigen having an apparent molecular weight of 16±2 kda, a specific antibody, and its use for the detection of said antigen
JP2003502643A (en) Assay
CN110540598B (en) Haemophilus influenzae Elisa detection kit based on surface protein antibody of haemophilus influenzae and preparation method

Legal Events

Date Code Title Description
A02 Decision of refusal

Effective date: 20040406

Free format text: JAPANESE INTERMEDIATE CODE: A02